Alector presents al001 (latozinemab) data from the ftd-c9orf72 cohort of the infront-2 phase 2 clinical trial

Treatment with al001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients

ALEC Ratings Summary

ALEC Quant Ranking